Mi2-β, a critical ATP-dependent helicase component of the nucleosome remodeling and deacetylase (NuRD) complex, is pivotal in regulating chromatin structure and thereby modulating gene expression. This enzyme contributes to the dynamic remodeling of nucleosomes, allowing for the precise control of transcriptional activities necessary for various cellular processes such as differentiation, proliferation, and DNA repair. The NuRD complex, of which Mi2-β is an essential part, integrates chromatin remodeling with histone deacetylation to maintain the epigenetic integrity and transcriptional repression of specific gene sets. Through its action, Mi2-β directly influences the accessibility of transcription factors to DNA, playing a crucial role in the epigenetic regulation of gene expression and in the maintenance of cell-type specific programming. The balanced activity of Mi2-β within the NuRD complex is therefore fundamental to the proper execution of cellular functions and the maintenance of genomic stability.
The inhibition of Mi2-β's function can disrupt the delicate balance of chromatin remodeling and transcriptional regulation, leading to aberrant gene expression patterns associated with various pathologies. Inhibition can occur through multiple mechanisms, including the competitive binding of molecules that directly interfere with the ATPase activity of Mi2-β, thereby hindering its helicase function and the subsequent remodeling of nucleosomes. Additionally, alterations in the expression levels or post-translational modifications of Mi2-β or other NuRD complex components can impact the complex's assembly, localization, and chromatin-binding affinity, indirectly inhibiting Mi2-β's activity. Furthermore, the interaction with inhibitory proteins or non-coding RNAs that sequester Mi2-β away from its target sites on chromatin can also result in the functional inhibition of the NuRD complex. Such mechanisms of inhibition underscore the complexity of regulating Mi2-β activity and the significance of its role in maintaining cellular homeostasis.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Novobiocin | 303-81-1 | sc-362034 sc-362034A | 5 mg 25 mg | $96.00 $355.00 | ||
Inhibitor of Hsp90 that indirectly modulates Mi2-β through disruption of protein folding and stability, leading to reduced Mi2-β activity. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Histone deacetylase inhibitor impacting Mi2-β indirectly by altering histone acetylation, affecting chromatin structure and gene expression. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
Proteasome inhibitor influencing Mi2-β by preventing protein degradation, leading to increased Mi2-β levels and altered cellular functions. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $56.00 $212.00 $764.00 | 24 | |
Inhibitor of MDM2, indirectly affecting Mi2-β by stabilizing p53 and influencing downstream pathways related to Mi2-β activity. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $260.00 $925.00 | 5 | |
Inhibitor of p300/CBP histone acetyltransferase, indirectly impacting Mi2-β by modulating acetylation levels and chromatin structure. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
Specific EZH2 inhibitor affecting Mi2-β indirectly by targeting the Polycomb Repressive Complex 2 (PRC2) and altering chromatin structure. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Modulates Mi2-β indirectly by influencing retinoic acid receptors and downstream signaling pathways, impacting Mi2-β expression and activity. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
Bromodomain and extraterminal (BET) family inhibitor indirectly influencing Mi2-β by disrupting acetylation-dependent protein interactions. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
Dual inhibitor of lysine-specific demethylase 1 (LSD1) and histone deacetylases, indirectly impacting Mi2-β by modulating histone modifications. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Histone deacetylase inhibitor indirectly influencing Mi2-β by altering histone acetylation patterns and chromatin structure. | ||||||